小鼠物种特异性控制肝细胞癌发生与代谢:FGF19/FGF15 的作用
研究通过腺相关病毒载体在 db/db、饮食诱导肥胖和 Mdr2 缺陷三种小鼠模型中持续表达人 FGF19 或鼠 FGF15,比较两者对肝细胞癌发生和代谢的调控。结果显示两者均抑制胆汁酸合成(均 p<0.001),但 FGF15 缺乏 FGF19 在 db/db 小鼠中的降 HbA1c 和 β 细胞保护作用,且 FGF15 在三种模型中均未诱导肝细胞癌,即使暴露水平超药理剂量。作者认为 FGF19 与 FGF15 的物种差异可能限制小鼠模型用于 FXR/FGF19 通路研究,并强调需在人体中评估该通路的安全性和有效性。
要点
- FGF19 与 FGF15 均抑制胆汁酸合成,两者 p<0.001。
- FGF15 在 db/db 小鼠中缺乏 FGF19 的降 HbA1c 和 β 细胞保护作用。
- FGF15 在三种代谢病小鼠模型中均未诱导肝细胞癌,即使超药理暴露。
核心结论
- FGF19 与 FGF15 之间存在根本性的物种相关差异,可能限制小鼠模型用于 FXR/FGF19 通路研究的适用性;作者强调需在人体中评估该通路的安全性和有效性。
研究设计与样本
- 通过腺相关病毒介导的基因递送,在 db/db、饮食诱导肥胖和 Mdr2 缺陷三种小鼠模型中持续暴露于 FGF19 或 FGF15,评估致瘤性。
- 在 db/db 小鼠中表征葡萄糖、血红蛋白 A1c 和 β 细胞质量;在饮食诱导肥胖小鼠中评估氧消耗、能量消耗和体成分;在 Mdr2 缺陷小鼠中检测血清碱性磷酸酶、丙氨酸氨基转移酶和天冬氨酸氨基转移酶。
- 还测定了参与胆汁酸合成和肝细胞癌发生的 key 蛋白编码基因的表达谱。
主要发现
- FGF15 和 FGF19 均抑制胆汁酸合成,两者 p<0.001。
- 在 db/db 小鼠中,鼠 FGF15 缺乏人 FGF19 的保护作用,如体重非依赖的 HbA1c 降低和 β 细胞保护。
- 与 FGF19 不同,FGF15 在 db/db、饮食诱导肥胖和 Mdr2 缺陷三种代谢病小鼠模型中均未诱导肝细胞癌,即使在超药理暴露水平。
关键数值与推荐
- FGF15 和 FGF19 抑制胆汁酸合成,两者 p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Bile acid nuclear receptor farnesoid X receptor (FXR) is a key molecular mediator of many metabolic processes, including the regulation of bile acid, lipid and glucose homeostasis. A significant component of FXR-mediated events essential to its biological activity is attributed to induction of the enteric endocrine hormone fibroblast growth factor (FGF)19 or its rodent ortholog, FGF15. In this report, we compared the properties of human FGF19 and murine FGF15 in the regulation of hepatocarcinogenesis and metabolism in various mouse models of disease. METHODS: Tumorigenicity was assessed in three mouse models (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient) following continuous exposure to FGF19 or FGF15 via adeno-associated viral-mediated gene delivery. Glucose, hemoglobin A1c and β-cell mass were characterized in db/db mice. Oxygen consumption, energy expenditure, and body composition were evaluated in diet-induced obese mice. Serum levels of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase were assessed in Mdr2-deficient mice. Expression profiles of genes encoding key proteins involved in bile acid synthesis and hepatocarcinogenesis were also determined. RESULTS: Both FGF15 and FGF19 hormones repressed bile acid synthesis (p<0.001 for both). However, murine FGF15 lacked the protective effects characteristic of human FGF19 in db/db mice with overt diabetes, such as weight-independent HbA1c-lowering and β-cell-protection. Unlike FGF19, FGF15 did not induce hepatocellular carcinomas (HCC) in three mouse models of metabolic diseases (db/db, diet-induced obese, and multi-drug resistance 2 [Mdr2]-deficient mice), even at supra-pharmacological exposure levels. CONCLUSIONS: Fundamental species-associated differences between FGF19 and FGF15 may restrict the relevance of mouse models for the study of the FXR/FGF19 pathway, and underscore the importance of clinical assessment of this pathway, with respect to both safety and efficacy in humans. LAY SUMMARY: Activation of the nuclear receptor, FXR, leads to the production of a hormone called fibroblast growth factor 19 (FGF19) and subsequently regulation of multiple metabolic processes. Synthetic activators of FXR have been recently approved or are currently in clinical development for treatment of chronic liver diseases, including primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). The safety of these activators was partly assessed in mice exposed for prolonged periods of time. However, the results of this study show that mouse FGF15 and human FGF19 exhibit fundamentally different biological activities in mice. This could raise the concern of relying on rodent models for safety assessment of FXR activators. The potential risk of HCC development in patients treated with FXR agonists may need to be monitored.
引用
- Zhou M, Luo J, Chen M, et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J Hepatol. 2017. PMID: 28189755. doi:10.1016/j.jhep.2017.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。